In our second interview, Dr. Leyfman shared his research on COVID-19 and cancer patients presented at the American Society of Clinical Oncology’s Annual Meeting or ASCO 2021. He discussed a radically different approach with an experimental cellular therapy, mesenchymal stem cells, which demonstrated a 91% overall survival and 100%
This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) reported analysis of retrospective data from 91 adult patients in France with lymphoma or chronic lymphocytic leukemia (CLL) who enrolled in a study of antibody responses, measured two or more weeks after receiving second or
In the first half of January 2022, Dr. Sameer Parikh from Mayo, Rochester, MN, discusses the present state of affairs related to COVID-19 for those with chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL.
Paxlovid (nirmatrelvir co-packaged with ritonavir) was recently issued an Emergency Use Authorization (EUA) for the treatment of mild-to-moderate COVID-19 in those at high risk to progress to more severe disease, such as those with chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL.
We all know that there are significant shortages of the potentially lifesaving medications for treatment and prevention of COVID-19 infections in the immunocompromised, including those with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL).